Ray Prudo, M.D. 13D and 13G filings for Akari Therapeutics, Plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-04 4:52 pm Purchase | 2026-03-02 | 13D | Akari Therapeutics, Plc AKTX | Ray Prudo, M.D. | 8,391,326,467 8.900% | 3,464,725,667 (+70.33%) | Filing |
| 2025-02-14 5:00 pm Purchase | 2024-11-14 | 13D | Akari Therapeutics, Plc AKTX | Ray Prudo, M.D. | 4,926,600,800 9.300% | 4,926,600,800 (New Position) | Filing |